Skip to main content
Avenue Therapeutics
  • Home Redirect
  • About
    • Management Team
    • Board of Directors
  • Publications
    • Publications
  • Investors
    • Investors Home
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Info
      • Stock Quote & Chart
    • Financial Information
      • Financial Reports
      • SEC Filings
      • Interactive Financials
    • Corporate Governance
      • Governance Documents
      • Committee Composition
      • Management Team
      • Board of Directors
    • Investor Resources
      • FAQs
      • Email Alerts & RSS Feeds
      • Contact Us
  • Contact Us
  • Home Redirect
  • About
    • Management Team
    • Board of Directors
  • Publications
    • Publications
  • Investors
    • Investors Home
    • Press Releases
    • Events & Presentations
      • Events
      • Presentations
    • Stock Info
      • Stock Quote & Chart
    • Financial Information
      • Financial Reports
      • SEC Filings
      • Interactive Financials
    • Corporate Governance
      • Governance Documents
      • Committee Composition
      • Management Team
      • Board of Directors
    • Investor Resources
      • FAQs
      • Email Alerts & RSS Feeds
      • Contact Us
  • Contact Us

Press Releases

Normal
Press Release RSS Feed (opens in new window)
Press release year list 2021 2020 2019 2018 2017 2015
November 9, 2017
Avenue Therapeutics Reports Third Quarter 2017 Financial Results and Recent Corporate Highlights
September 27, 2017
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain
August 15, 2017
Avenue Therapeutics Announces Appointment of Joseph Vazzano as Vice President of Finance and Corporate Controller (principal financial and accounting officer)
August 11, 2017
Avenue Therapeutics Reports Second Quarter 2017 Financial Results and Recent Corporate Highlights
July 3, 2017
Fortress Biotech Announces Appointment of Lucy Lu, MD, as President and Chief Executive Officer of Subsidiary Avenue Therapeutics
June 30, 2017
Avenue Therapeutics Completes Initial Public Offering
June 26, 2017
Avenue Therapeutics Prices Initial Public Offering of $33,000,000 of Common Stock
May 19, 2017
Avenue Therapeutics Receives Notice of Allowance for a New Patent Application Covering Methods of Administration for Intravenous Tramadol
Download PDF format download (opens in new window)
January 3, 2017
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol
Download PDF format download (opens in new window)

Social

Investor Contact

Lucy Lu, M.D., CEO
ir@avenuetx.com

Email Alerts

To receive notifications via email, enter your email address and select at least one subscription below. After submitting your information, you will receive an email. You must click the link in the email to activate your subscription. You can sign up for additional subscriptions at any time.

* Required

*
*
 
Enter the code shown above.
*

Email Alert Sign Up Confirmation

  • Privacy
  • Disclaimer
  • Contact Us
Copyright © Avenue Therapeutics
Powered By Q4 Inc. 5.52.0.6 (opens in new window)